Pirodavir

• CAT Number: I000970
• CAS Number: 124436-59-5
• Molecular Formula: C21H27N3O3
• Molecular Weight: 369.5
• Purity: ≥95%
• Target: broad-spectrum antipicornavirus; capsid-binding inhibitor
• Solubility: DMSO 67 mg/mL; Water <1 mg/mL; Ethanol 7 mg/mL
• Storage: -20°C
• IC50: Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2].
• InChI: InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3
• InChIKey: KCHIOGFOPPOUJC-UHFFFAOYSA-N
• SMILES: CCOC(C1=CC=C(OCCC2CCN(C3=CC=C(C)N=N3)CC2)C=C1)=O

Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds; potent human rhinovirus (HRV) capsid-binding inhibitor.IC50 Value: Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2].Target: broad-spectrum antipicornavirus; capsid-binding inhibitorpirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent [1].in vitro: R-77975/’s predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication [2].in vivo: Adults with symptoms of < or = 2 days/’ duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times daily for 5 days. In people with laboratory-documented rhinovirus colds (53 in the pirodavir group, 55 in the placebo group), no significant differences in the resolution of respiratory symptoms were apparent between the groups. The median duration of illness was 7 days in each group. Similarly, scores for individual symptoms found no differences in favor of pirodavir during or after treatment [3].Clinical trial:

Reference

1:In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Lacroix C, Laconi S, Angius F, Coluccia A, Silvestri R, Pompei R, Neyts J, Leyssen P.Virol J. 2015 Jul 14;12:106. doi: 10.1186/s12985-015-0330-4. PMID: 26169596 Free PMC Article2:Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Bernard A, Lacroix C, Cabiddu MG, Neyts J, Leyssen P, Pompei R.Antivir Chem Chemother. 2015 Apr;24(2):56-61. doi: 10.1177/2040206615589035. Epub 2015 Jun 11. PMID: 26071135 3:In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA.Antimicrob Agents Chemother. 2004 May;48(5):1766-72. PMID: 15105133 Free PMC Article4:Stabilisation of poliovirus with pirodavir. Rombaut B, Andries K, Boeyé A.Dev Biol Stand. 1996;87:173-80. PMID: 8854015 5:Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, Andries K.Antimicrob Agents Chemother. 1995 Feb;39(2):290-4. PMID: 7726484 Free PMC Article6:Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Hayden FG, Andries K, Janssen PA.Antimicrob Agents Chemother. 1992 Apr;36(4):727-32. PMID: 1503435 Free PMC Article7:In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA.Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. PMID: 1317142 Free PMC Article